In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to boost NHL clinical trial diversity among underserved communities Presenters: Julio C. Chavez, MD, MS Associate Member Department of Malignant Hematology ICE-T Clinical Research Medical Director for Hematologic Malignancies H. Lee Moffitt Cancer Center and Research Institute Associate Professor University of South Florida Tampa, Florida Alan Skarbnik, MD Director, Lymphoma and CLL Program Director, Immune Effector Cell Therapeutics Program Novant Health Cancer Institute Charlotte, North Carolina Content based on an online CME program supported by educational grants from Bristol-Myers Squibb. Link to full program: https://bit.ly/45YXoZI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
